NASDAQ:GDRX - GoodRx Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $50.00
Forecasted Upside: 32.87 %
Number of Analysts: 16
Breakdown:
1 Sell Ratings
7 Hold Ratings
8 Buy Ratings
0 Strong Buy Ratings

^$37.63 As of 06/18/2021 01:00 AM ET

▼ -0.26 (-0.69%)

1 month | 3 months | 12 months

Get New GoodRx Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for GDRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GDRX

^$50.00

▲ +32.87% Upside Potential

This price target is based on 16 analysts offering 12 month price targets for GoodRx in the last 3 months. The average price target is $50.00, with a high forecast of $70.00 and a low forecast of $29.00. The average price target represents a 32.87% upside from the last price of $37.63.

Hold

The current consensus among 16 contributing investment analysts is to hold stock in GoodRx.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/28/2019

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/27/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/25/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/23/2020

0 strong buy ratings
6 buy ratings
6 hold ratings
1 sell ratings

Ratings as of

12/22/2020

0 strong buy ratings
7 buy ratings
6 hold ratings
1 sell ratings

Ratings as of

3/22/2021

0 strong buy ratings
8 buy ratings
6 hold ratings
1 sell ratings

Ratings as of

5/21/2021

0 strong buy ratings
8 buy ratings
7 hold ratings
1 sell ratings

Ratings as of

6/20/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/27/2021	Robert W. Baird	Initiated Coverage	Neutral	$37.00	Low
5/18/2021	Credit Suisse Group	Lower Price Target	Outperform ➝ Outperform	$50.00 ➝ $45.00	Low
5/14/2021	SVB Leerink	Lower Price Target	Outperform	$61.00 ➝ $56.00	High
5/14/2021	Royal Bank of Canada	Lower Price Target	Outperform	$56.00 ➝ $50.00	High
5/14/2021	Barclays	Lower Price Target	Equal Weight	$43.00 ➝ $33.00	High
5/14/2021	Citigroup	Boost Price Target	Buy	$53.00 ➝ $70.00	High
5/10/2021	Cowen	Lower Price Target	Outperform	$70.00 ➝ $58.00	High
3/15/2021	Credit Suisse Group	Boost Price Target	Outperform	$49.00 ➝ $50.00	Low
3/12/2021	Barclays	Boost Price Target		$35.00 ➝ $45.00	Low
3/12/2021	Deutsche Bank Aktiengesellschaft	Boost Price Target	Hold	$31.00 ➝ $37.00	High
3/4/2021	SVB Leerink	Reiterated Rating	Buy	$61.00	Medium
2/12/2021	Cowen	Boost Price Target	Outperform	$50.00 ➝ $70.00	Low
1/25/2021	Guggenheim	Initiated Coverage	Buy	$52.00	High
11/23/2020	The Goldman Sachs Group	Lower Price Target	Neutral	$49.00 ➝ $44.00	Low
11/20/2020	Credit Suisse Group	Lower Price Target	Outperform	$60.00 ➝ $49.00	Low
11/19/2020	Barclays	Lower Price Target	Equal Weight	$55.00 ➝ $35.00	High
11/19/2020	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$56.00	High
11/18/2020	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$36.00	Low
11/18/2020	JPMorgan Chase & Co.	Reiterated Rating	Neutral ➝ Underweight	$29.00	Low
11/18/2020	Deutsche Bank Aktiengesellschaft	Lower Price Target	Hold	$50.00 ➝ $31.00	High
11/17/2020	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight	$29.00	High
10/19/2020	The Goldman Sachs Group	Initiated Coverage	Neutral	$48.00	High
10/19/2020	Cowen	Initiated Coverage	Outperform	$63.00	High
10/19/2020	Morgan Stanley	Initiated Coverage	Overweight	$57.00	High
10/19/2020	JPMorgan Chase & Co.	Initiated Coverage	Neutral	$59.00	High
10/19/2020	Raymond James	Initiated Coverage	Equal Weight ➝ Market Perform	$57.00 ➝ $61.00	High
10/19/2020	Credit Suisse Group	Initiated Coverage	Outperform	$60.00	High
10/19/2020	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Hold	$50.00	High
10/19/2020	Royal Bank of Canada	Initiated Coverage	Sector Perform	$55.00	High
10/19/2020	Bank of America	Initiated Coverage	Neutral	$58.00	High
10/19/2020	UBS Group	Initiated Coverage	Buy	$64.00	High
10/19/2020	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Initiated Coverage	Buy	$70.00	High
10/19/2020	Barclays	Initiated Coverage	Equal Weight	$53.00	High
10/19/2020	SVB Leerink	Initiated Coverage	Outperform	$61.00	High

(Data available from 6/20/2016 forward)

GoodRx Holdings, Inc., through its subsidiaries, provides information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including telehealth services. The company serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. GoodRx Holdings, Inc. was incorporated in 2015 and is based in Santa Monica, California.

Today's Range

Now: $37.63

$37.09

$38.51

50 Day Range

MA: $36.44

$28.27

$41.18

52 Week Range

Now: $37.63

$26.66

$64.22

Volume

2,790,081 shs

Average Volume

2,133,098 shs

Market Capitalization

$14.79 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of GoodRx?

The following Wall Street research analysts have issued reports on GoodRx in the last year: Bank of America Co., Barclays PLC, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cowen Inc, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Guggenheim, JPMorgan Chase & Co., Morgan Stanley, Raymond James, Robert W. Baird, Royal Bank of Canada, SVB Leerink LLC, The Goldman Sachs Group, Inc., UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for GDRX.

What is the current price target for GoodRx?

16 Wall Street analysts have set twelve-month price targets for GoodRx in the last year. Their average twelve-month price target is $50.00, suggesting a possible upside of 32.9%. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell has the highest price target set, predicting GDRX will reach $70.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $29.00 for GoodRx in the next year.
View the latest price targets for GDRX.

What is the current consensus analyst rating for GoodRx?

GoodRx currently has 1 sell rating, 7 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GDRX, but not buy more shares or sell existing shares.
View the latest ratings for GDRX.

What other companies compete with GoodRx?

Other companies that are similar to GoodRx include Workday, Bilibili, Verisk Analytics, RingCentral, StoneCo, PagSeguro Digital, Zendesk, Clarivate, Five9, Zynga, Pegasystems, Proofpoint, Playtika, DXC Technology and Globant.

How do I contact GoodRx's investor relations team?

GoodRx's physical mailing address is 233 WILSHIRE BLVD. SUITE 990, SANTA MONICA CA, 90401. The company's listed phone number is 855-268-2822 and its investor relations email address is [email protected] The official website for GoodRx is www.goodrx.com.